Education
About Us
Working with TipRanks
Follow Us
Inspire Medical Systems (INSP)
NYSE:INSP
Top Page
Inspire Medical Systems
(NYSE:INSP)
Select Model
Select Model
Rating:66Neutral
Price Target:
$73.00
▲(13.16% Upside)
Action:ReiteratedDate:02/14/26
The score is supported by strong financial performance (profitability inflection, high gross margins, and a conservative balance sheet) and a reasonable earnings multiple, but is pulled down by very weak technicals (sharp downtrend, oversold conditions) and elevated 2026 execution risk from reimbursement/coding uncertainty and near-term disruption highlighted on the earnings call.
Positive Factors
High gross margins & profitability
Very high gross margins (~85%) and a clear move into profitability give Inspire structural pricing power and cushion against revenue variability. Durable margin strength funds R&D, supports reinvestment and shareholder returns, and reduces break-even sensitivity to short-term volume swings.
Conservative balance sheet and capital returns
Low leverage and a sizeable cash balance ($405M) provide financial flexibility to fund commercialization, R&D and working capital through reimbursement cycles. Material buybacks in 2025 reflect strong free capital allocation discipline and a buffer against near-term revenue shocks.
Inspire 5 clinical leadership & product roadmap
Clinical superiority, higher responder rates and improved reliability materially strengthen physician adoption and patient outcomes. Widespread center adoption, MRI compatibility and an Inspire 6 program create a durable competitive moat, supporting sustained procedure growth and market share.
Negative Factors
Coding & reimbursement uncertainty
A coding clarification shifting procedures to CPT 64582 with a -52 modifier risks a significant professional fee haircut (10%–50%), which can structurally reduce physician economics and case willingness. The uncertainty widens guidance and can depress volumes and margins until resolved.
Concentrated U.S. exposure & prior-authorization headwinds
With ~95% of revenue from the U.S., Medicare pilots like WISER and inconsistent MAC coding create persistent operational barriers. Prior-authorizations, denials and mapping variability can reduce procedures for a core patient cohort, making growth highly dependent on U.S. payer fixes.
Free cash flow volatility & margin sensitivity
FCF fell materially in 2025 and covers only ~67% of net income, indicating earnings are not fully matched by cash generation. Operating margin (~5.6%) trails net margin, so results are sensitive to operating expense leverage and reimbursement shocks, constraining durable free cash availability.
Inspire Medical Systems (INSP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.84B
Dividend YieldN/A
Average Volume (3M)1.45M
Price to Earnings (P/E)13.0
Beta (1Y)0.44
Revenue Growth16.81%
EPS Growth34.90%
CountryUS
Employees1,246
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)1.65
Shares Outstanding28,589,290
10 Day Avg. Volume1,375,204
30 Day Avg. Volume1,448,023
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.47
Price to Sales (P/S)2.97
P/FCF Ratio34.52
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue2.01
Enterprise Value/Gross Profit2.35
Enterprise Value/Ebitda26.24
Forecast
1Y Price Target
$91.62Price Target Upside42.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
EPS Forecast (FY)1.94
Revenue Forecast (FY)$966.85M
Inspire Medical Systems Business Overview & Revenue Model
Company DescriptionInspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, a closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.
How the Company Makes MoneyInspire Medical Systems generates revenue primarily through the sale of its Inspire therapy system, which includes the device itself, surgical implantation, and follow-up patient management services. The company operates on a direct sales model, selling its products to hospitals and sleep clinics, and it may also collaborate with healthcare providers for training and support services. Additionally, Inspire benefits from reimbursement programs by insurance companies that cover the cost of the Inspire system for eligible patients, which further drives its revenue. The growth in awareness of sleep apnea and the increasing acceptance of innovative treatments also contribute significantly to the company's earnings.
Inspire Medical Systems Key Performance Indicators (KPIs)
Inspire Medical Systems Earnings Call Summary
Earnings Call Date:Feb 11, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 05, 2026
Earnings Call Sentiment Neutral
The call presents a balanced picture: strong 2025 financial results, cash generation, buybacks, and clear clinical and commercial traction for Inspire 5 (training, high center adoption, superior clinical metrics). However, material near-term reimbursement and coding uncertainty (transition to CPT 64582 with a -52 modifier), the WISER prior-authorization pilot, and inconsistent claims processing introduce significant short- to medium-term risk that widened 2026 guidance and could constrain physician willingness and early-year procedures. Management has a dual-path remediation plan (short-term payer engagement to reduce the modifier impact and long-term pursuit of a new CPT code), plus product and operational levers, but the timing and magnitude of reimbursement outcomes remain the key risk to achieving the higher end of guidance.Q4-2025 Updates
Positive Updates
Revenue Growth
Fourth quarter revenue increased 12% to $269 million; full year 2025 revenue increased 14% to $912 million, driven by growth at existing centers and new center additions.
Profitability and Earnings Performance
Fourth quarter delivered positive operating income and earnings. Q4 net income per diluted share rose by $3.51 to $4.66 and full year net income per diluted share rose by $3.09 to $4.89.
Adjusted Earnings and Cash Flow
Q4 adjusted net income per diluted share increased $0.51 to $1.65 and full year adjusted EPS increased $0.80 to $2.42. Fourth quarter operating cash flow was $52 million, bringing full year operating cash flow to $117 million.
Capital Allocation and Balance Sheet Strength
Completed $50 million of share repurchases in Q4 and $175 million for the full year; ended the quarter with $405 million in cash and investments, supporting investments for growth.
Inspire 5 Clinical and Reliability Performance
Inspire 5 showed clinical superiority vs. Inspire 4: reduced surgical time, significantly improved inspiratory overlap, and a 79.5% responder rate (Sher criteria) in the Singapore study vs. 66% in STAR pivotal trial. System reliability improved in 2025 with device explants at 0.5% and revisions at 1.5%.
Successful U.S. Launch Execution
Physician training complete, contracting over 95% complete for centers, SleepSync onboarding complete for over 90% of centers, and over 90% of centers implanting Inspire 5; expect stable product inventory for Inspire 5 through 2026.
Product and R&D Progress
Received FDA approval for 3 Tesla MRI compatibility; testing prior-authorization feature in SleepSync; announced Inspire 6 program for sleep detection and auto-activation targeting improved adherence.
Operational Discipline
Q4 and full year operating margins improved driven by sales leverage and a higher sales mix of Inspire 5 systems; management cites disciplined spending and targeted commercial reorganization (295 U.S. territories, 275 field clinical reps).
2026 Financial Guidance (Range Provided)
Management provided a full-year 2026 revenue outlook of $950 million to $1,000 million (4% to 10% growth), adjusted operating margin guidance of 6% to 8%, and adjusted EPS guidance of $1.85 to $2.35, while disclosing assumptions and risks.
Commercial and Global Footprint
U.S. remains the core market (Q4 U.S. revenue $256.9M, ~95% of revenue); management continues focus on expanding provider capacity, training advanced practice providers, and certifying additional surgeons to treat more patients.
Negative Updates
Coding and Reimbursement Uncertainty
Recent clarification indicates Inspire 5 procedures should transition to CPT code 64582 with a -52 modifier; company estimates the professional fee reduction could range approximately 10% to 50% of the base rate, with actual impact varying by MAC and payer.
Potential Physician Willingness Impact
Management warns that a significant decrease in the professional fee from the -52 modifier could reduce physicians' willingness to perform Inspire 5 procedures and limit case volume, particularly affecting private-practice surgeons who rely on professional fees.
WISER Program Disruption
Medicare WISER prior-authorization pilot in six states has led to denials and delays due to portal/AI inconsistencies and coding issues, affecting Medicare patient procedures in Q1 2026 and adding short-term headwinds.
Widened 2026 Guidance Due to Reimbursement Risk
Company widened 2026 revenue guidance to reflect broad possible outcomes driven primarily by coding uncertainty and the potential physician fee haircut (low end assumes a 50% professional fee cut).
Inconsistent Claims and Mapping Across MACs
Claims experience is inconsistent—procedures paid under 64568 and 64582, some claims denied or re-priced; none of the MACs have fully mapped the -52 modifier in policy, creating near-term billing variability.
Timing Risk for New CPT Code
Long-term solution is a new Category I CPT code, but that process (including RUC valuation) would not take effect until 01/01/2028, leaving a multi-year interim reimbursement risk window.
Limited Viability of Category III or Miscellaneous Codes
Management chose not to pursue a Category III or miscellaneous temporary code because it would likely introduce unstable and variable reimbursement across facilities, reducing clarity for facility payments.
First Quarter Outlook and Near-Term Earnings Pressure
Management expects Q1 2026 revenue to be approximately flat year-over-year and anticipates a net loss in Q1 due to coding uncertainty and forecasted higher operating expenses, with sequential improvement expected later in the year.
Operational Constraints Around Legacy Product
While inventory of Inspire 4 exists, management notes parts obsolescence will limit the ability to restart full-scale Inspire 4 production long term if needed, constraining fallback options.
Tax and Stock-Based Compensation Volatility
Effective tax rate assumptions are wide (44%–49%) and adjusted rate 26%–28%; the tax impact of stock-based compensation is concentrated in Q1 and could materially swing GAAP tax expense/benefit, adding earnings volatility.
Company Guidance
Management revised 2026 guidance to full‑year revenue of $950M–$1,000M (4%–10% growth), reflecting coding uncertainty (transition to CPT 64582 with a -52 modifier) and WISER-related Q1 disruption; they expect Q1 revenue roughly flat YoY and a Q1 net loss with sequential improvement thereafter and the strongest revenue and profit in Q4. They forecast adjusted operating margin of 6%–8%, GAAP net income per diluted share of $1.23–$1.81 and adjusted net income per diluted share of $1.85–$2.35, assume an effective tax rate of 44%–49% (adjusted 26%–28%), weighted‑average diluted shares of ~29.4M, and capex of $45M–$50M. The revenue range models a physician professional‑fee haircut of 10% (high end) to 50% (low end), and management cautioned that stock‑based compensation can materially affect the reported tax rate (concentrated in Q1).Inspire Medical Systems Financial Statement Overview
Summary
Strong fundamentals with rapid scale and a clear move into profitability, supported by very high gross margins and low leverage. The main offset is cash-flow quality/consistency: free cash flow fell in 2025 and covers only about two-thirds of net income, adding monitoring risk despite positive operating cash flow.Income Statement
INSP shows a strong profitability inflection and accelerating scale. Annual revenue expanded from $115M (2020) to $912M (2025), with growth still robust in 2025 (+333% vs. prior year per provided data). Profitability has materially improved: the company moved from losses in 2020–2023 to solid profits in 2024–2025, with 2025 net margin at ~16% and gross margin remaining very high (~85%). A key watch-out is that operating profitability remains more modest than net income suggests (2025 operating margin ~5.6%), implying results may be more sensitive to operating expense leverage and other below-the-line benefits.86
Very Positive
Balance Sheet
The balance sheet looks conservative and strengthening. Leverage is low (2025 debt-to-equity ~0.08) and equity has grown meaningfully over time ($229M in 2020 to $781M in 2025), supporting financial flexibility. Returns on equity improved sharply with the move to profitability (2025 ROE ~18.6%). The main weakness is that total debt has risen in absolute dollars in recent years (to ~$60M in 2025), though it remains small relative to the equity base.82
Very Positive
Cash Flow
Cash generation is positive and improving versus early years, with 2025 operating cash flow at ~$117M and free cash flow at ~$78M. However, cash conversion has weakened versus 2024: free cash flow declined ~21% in 2025 and free cash flow covers only about two-thirds of net income (~0.67), indicating earnings quality is good but not fully matched by free cash generation. Operating cash flow remains above net income (coverage ~1.22 in 2025), which is supportive, but the year-to-year volatility in free cash flow is a risk to monitor.71
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 911.98M | 802.80M | 624.80M | 407.86M | 233.39M |
| Gross Profit | 778.76M | 679.82M | 528.22M | 341.74M | 200.12M |
| EBITDA | 64.91M | 65.03M | -17.06M | -40.73M | -38.62M |
| Net Income | 145.42M | 53.51M | -21.15M | -44.88M | -42.04M |
Balance Sheet | |||||
| Total Assets | 907.32M | 808.38M | 676.81M | 564.88M | 295.08M |
| Cash, Cash Equivalents and Short-Term Investments | 308.27M | 445.55M | 460.38M | 451.41M | 214.47M |
| Total Debt | 32.16M | 31.79M | 24.85M | 16.41M | 34.09M |
| Total Liabilities | 126.16M | 118.69M | 104.30M | 68.87M | 66.04M |
| Stockholders Equity | 781.16M | 689.70M | 572.51M | 496.01M | 229.05M |
Cash Flow | |||||
| Free Cash Flow | 78.48M | 91.12M | 1.02M | 2.47M | -24.79M |
| Operating Cash Flow | 116.98M | 130.25M | 24.65M | 11.57M | -20.12M |
| Investing Cash Flow | 21.45M | -113.12M | -294.82M | -19.60M | 29.14M |
| Financing Cash Flow | -183.45M | -52.39M | 13.95M | 235.08M | 14.95M |
Inspire Medical Systems Technical Analysis
Negative
64.51
Price Trends
82.06
Negative
89.15
Negative
100.89
Negative
Market Momentum
-6.15
Negative
41.93
Neutral
39.40
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INSP, the sentiment is Negative. The current price of 64.51 is below the 20-day moving average (MA) of 64.62, below the 50-day MA of 82.06, and below the 200-day MA of 100.89, indicating a bearish trend. The MACD of -6.15 indicates Negative momentum. The RSI at 41.93 is Neutral, neither overbought nor oversold. The STOCH value of 39.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INSP.
Inspire Medical Systems Risk Analysis
Inspire Medical Systems disclosed 60 risk factors in its most recent earnings report. Inspire Medical Systems reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Inspire Medical Systems Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | $4.98B | 29.91 | 54.24% | ― | 41.20% | 173.53% | |
68 Neutral | $3.86B | -15.77 | -19.24% | ― | 8.97% | -1024.86% | |
66 Neutral | $1.84B | 12.99 | 19.77% | ― | 16.81% | 34.90% | |
64 Neutral | $2.98B | 30.21 | 6.11% | ― | 7.81% | -26.32% | |
54 Neutral | $4.32B | -94.80 | -36.57% | ― | 25.45% | 66.62% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $1.28B | -13.19 | -24.89% | ― | 50.07% | 21.22% |
* Healthcare Sector Average
INSP
Inspire Medical Systems
64.51
-117.93
-64.64%
ITGR
Integer Holdings
86.68
-33.53
-27.89%
LIVN
LivaNova
70.60
28.88
69.22%
IRTC
Irhythm Technologies
133.75
24.65
22.59%
TMDX
TransMedics Group
145.26
75.93
109.52%
PRCT
PROCEPT BioRobotics
22.69
-37.91
-62.56%
Inspire Medical Systems Corporate Events
Business Operations and StrategyStock BuybackFinancial DisclosuresRegulatory Filings and Compliance
Inspire Medical Updates Governance, Outlines 2026 Growth Outlook
Positive
Feb 11, 2026
Inspire Medical Systems reported on February 11, 2026 that it ended 2025 with solid momentum, driven by the full commercial launch of its Inspire V system, 12% fourth-quarter revenue growth to $269.1 million and 14% full-year revenue growth to $912.0 million, alongside rising gross margins and a swing to strong profitability supported by an $85.8 million fourth-quarter tax benefit. The company generated $117.0 million in full-year operating cash flow, repurchased $175 million of stock and guided 2026 revenue to $950 million–$1.0 billion with adjusted operating margin of 6%–8%, while acknowledging reimbursement headwinds from a coding clarification that shifts Inspire V procedures to CPT code 64582 with a -52 modifier, and separately moved to enhance shareholder governance by proposing board declassification and director removal rules aligned with Delaware law for a 2026 stockholder vote.
In preparation for this governance change, the board on February 5, 2026 approved amended bylaws, contingent on stockholder approval, that would eliminate the “for cause only” removal restriction and instead rely on the updated charter provisions. The company also disclosed plans to meet investors and analysts in February and March 2026 using a new investor presentation, underscoring management’s effort to communicate both the growth opportunity and reimbursement and margin dynamics as it seeks to sustain long-term profitable expansion and shareholder value creation.
The most recent analyst rating on (INSP) stock is a Buy with a $82.00 price target. To see the full list of analyst forecasts on Inspire Medical Systems stock, see the INSP Stock Forecast page.
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
Inspire Medical Systems Issues Strong Preliminary 2025 Revenue Results
Positive
Jan 12, 2026
On January 12, 2026, Inspire Medical Systems reported preliminary, unaudited revenue for the fourth quarter and full year 2025, indicating continued double‑digit growth and strong adoption of its fifth‑generation Inspire V system. Fourth-quarter 2025 revenue is expected to come in at approximately $268.9 million to $269.1 million, up about 12% from a year earlier, while full‑year 2025 revenue is anticipated in the range of $911.8 million to $912.0 million, representing roughly 14% growth over 2024. The company also issued initial 2026 guidance, projecting revenue between $1.003 billion and $1.013 billion, or 10% to 11% growth, and noted that this outlook does not yet factor in any potential upside from recent reimbursement developments, which remain subject to coding clarification. In a parallel leadership move, the board on January 9, 2026 approved the appointment of veteran finance executive Matt Osberg as Executive Vice President and Chief Financial Officer, effective after filing the 2025 Form 10‑K, with a compensation package that includes salary, bonus eligibility, equity incentives and change‑of‑control protections, while current CFO Richard Buchholz will serve as interim CFO through the completion of the 2025 annual report, underscoring a managed transition in the company’s financial leadership as it enters its next phase of growth.
The most recent analyst rating on (INSP) stock is a Buy with a $120.00 price target. To see the full list of analyst forecasts on Inspire Medical Systems stock, see the INSP Stock Forecast page.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.